Track record · closed signal

Novo Nordisk A/S (NVO) — closed signal from September 17, 2025

Partial Published before the outcome was known, scored automatically when the window closed on December 16, 2025.

Predicted vs. what happened

NVO price · publication thesis → realized outcomesplit-adjusted
$58.52 Published $70.22 Target $48.96 Window close $62.32 Peak
$58.00 – $59.50Entry zone — fair-value band
$58.52Published — price the day we called it
$70.22Target — the price the thesis aimed for
$62.32Peak — highest point inside the window, not a realized return
$48.96Window close — end-of-window price, context only

What happened

Partial

Reached 33% of the predicted growth at its peak, without hitting the target.

Peak price
$62.32
peak on September 19, 2025 — not a realized return
Peak gain
+6.5%
peak, from the publication price
Window close
$48.96
end-of-window price, context only
Days to target
—
Window
September 17, 2025 – December 16, 2025

The thesis — published September 17, 2025

Predicted growth
+20%
over the measurement window
Target price
$70.22
the price the thesis aimed for
Entry zone
$58.00 – $59.50
the fair-value band we waited for
Price at publication
$58.52
published September 17, 2025
Confidence
76%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Novo Nordisk is a leader in diabetes and weight-loss medicines, and the stock has been climbing. There has been lots more buying than usual. Europe just said Rybelsus also benefits heart health, and a late-stage study for cagrilintide showed meaningful weight loss, which can extend its product line. Even with Eli Lilly competing, demand looks strong, so the stock could stay firm over the next 0 to 3 months.

Primary drivers

  • Europe said Rybelsus also helps heart health, boosting its appeal
  • Late-stage study results showed strong weight loss for cagrilintide
  • Price trend looks healthy, with lots more buyers than usual right now
  • Strong long-term demand for GLP-1 drugs helps offset rivals in the space

How it played out

NVO: target was not reached

Lyra published NVO on 2025-09-17 at $58.52, looking for 20% growth in a short-term window. The thesis pointed to leadership in diabetes and weight-loss medicines, stronger buying, European support for Rybelsus in heart health, late-stage cagrilintide weight-loss data, and demand for GLP-1 drugs despite Eli Lilly competition.

The stock rose early, with a peak of $62.32 on 2025-09-19 and a peak gain of 6.5%. That stayed below the $70.22 target. It never got there. By 2025-12-16, NVO ended at $48.96. The thesis partially played out only in the early move, then missed the target.

What happened during the window

On 2025-11-05, Novo Nordisk reported third-quarter results and lowered its full-year outlook. On 2025-11-24, the company said oral semaglutide did not meet the primary goal in two late-stage Alzheimer's trials.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVO signals